Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q1- Text added to 2021 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
added, Anderson, antecedent, azacitidine, California, cladribine, cohort, compensatory, Eric, expansion, explore, Feldman, gastrointestinal, GI, goal, hematopoietic, IST, MD, melphalan, myelodysplastic, myeloma, myeloproliferative, neoplasm, potency, potent, readout, School, St, subset, syndrome, UC, unfit, venetoclax, Washington
Valuein 2021 Q1 filing- Value in 2021 Q2 filing
Original filings
Filing view